SynthesisEuropean journal of pediatrics2025
Efficacy of ileal bile acid transport inhibitors in children with Alagille syndrome: a meta-analysis.
Synthesis in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholestatic pruritus is a debilitating and treatment-resistant symptom in children with Alagille syndrome (ALGS), impairing sleep, psychosocial functioning, and quality of life. Current therapies are limited. Ileal bile acid transport inhibitors (IBATIs) are a novel therapeutic option, but evidence remains fragmented. This study aimed to assess the efficacy and safety of IBATIs (maralixibat and odevixibat) versus placebo in pediatric ALGS. Data sources from PubMed, EMBASE, and the Cochrane databases were searched up to November 30, 2024. Randomized placebo-controlled trials enrolling children with genetically or clinically confirmed ALGS and reporting validated pruritus or sBA outcomes were eligible. Two reviewers independently extracted data on design, participants, interventions, outcomes, and adverse events. The risk of bias was assessed using RoB2, and the certainty of evidence was evaluated with GRADE. Four RCTs including 138 children (mean age 6.1 years; 54% male) were analyzed. IBATIs reduced pruritus severity (SMD - 1.00; 95% CI - 1.64 to - 0.35), lowered sBA levels (MD - 91.09 µmol/L; 95% CI - 136.11 to - 46.06; P < .0001), and improved PedsQL scores (MD 10.13 points; 95% CI 4.88 to 15.39). Transient ALT elevations were observed; gastrointestinal events were common, but mild and self-limiting. The limitations of this study include heterogeneity in pruritus measures and dosing, short follow-up (≤ 24 weeks), and the use of non-interchangeable pruritus instruments across trials, requiring SMD pooling and precluding between-drug comparisons.
conclusionIBATIs are effective and well tolerated in pediatric ALGS, providing meaningful improvements in pruritus and quality of life. Longer trials are needed to confirm durability, safety, and transplant-free survival impact. WHAT IS KNOWN: • Children with Alagille syndrome often experience severe cholestatic pruritus with limited relief from current treatments. • Ileal bile acid transport inhibitors (IBATIs) have emerged as a promising targeted approach. WHAT IS NEW: • This meta-analysis shows that IBATIs significantly reduce pruritus and improve quality of life in affected children. • IBATIs are effective and well tolerated, supporting their use as a novel therapeutic option.
Indexed as
Identifiers
41201627What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.